Lancet Editorial: Safety of Swine Flu vaccine a Concern.

[Guest guest]

Dear Friends,

 

Activists are always accused of being unscientific. But we do go through medical journals and cross check what we post. During my 24 years of campaign against vaccines no one has ever been able to accuse me of wrong information.

 

I was reserving this Lancet editorial for such kind of accusations post my mails against the swine flu vaccine. Here is the mighty Lancet on the Swine Flu Vaccination. Will my dear friends refute this too?

 

I have placed so much of scientific evidence on these lists. Results of my years of tracking various reputed medical journals for peer reviewed articles. Why do my distractors remain silent in such moments? Why don't they act on such information and approach the government to stop the vaccination program that is harming the children of the nation?

 

Dialogue is a two way street my brothers. You just can't have it only your own way. Particularly when small children are the targets.

 

Regards,

Jagannath.

 

www.thelancet..com Vol 374 August 1, 2009EditorialLast week, Australia and the USA announced that theywould begin trials of an H1N1 vaccine. Vaccination againstH1N1 will be an important development in controllingthe impact of the pandemic. However, several thornyissues exist around vaccine manufacture and approval.All countries will require the vaccine but current globalmanufacturing capacity will not be able to meet thisdemand. Additionally, experts think that individuals mightneed two doses of the vaccine instead of one, reducingcapacity further. Vaccine manufacturers are also strugglingto produce good vaccine

yields with the H1N1 seed virus.One way to ease these supply problems is the useof adjuvants in a vaccine. On July 7, WHO’s StrategicAdvisory Group of Experts on Immunizationrecommended that vaccine formulated with oil-inwateradjuvants and live-attenuated influenza vaccinesshould be promoted to help increase the global supplyof a vaccine and because they are better at protectingagainst strain variations. Yet there are signs that the USAmight not follow this recommendation. “Adjuvant usewould be contingent upon showing that it was neededor clearly beneficialâ€, Jesse Goodman, acting chiefscientist and deputy commissioner of the Food and DrugAdministration told a press briefi ng on July 17. The USAmust support the use of dose-sparing strategies to avoiddepletion of an already short vaccine

supply.As well as availability, safety of an H1N1 vaccine is aconcern. Many national regulatory agencies have setupfast-track approval processes for the H1N1 vaccine,which means that a vaccine might be licensed withoutthe usual safety and efficacy data requirements. Vaccinesafety will therefore have to be monitored through postmarketingsurveillance. But some fear a repeat of the1976 H1N1 outbreak in the USA, where mass vaccinationwas associated with complications, which stopped thecampaign and led to the withdrawal of the vaccine.Countries need to assess carefully the risks andbenefi ts of rapid approval of an H1N1 vaccine, especiallysince the disease has so far been mild with most patientsmaking a full recovery. They must also ensure that theyhave strong post-marketing surveillance in place

beforerolling out a vaccine. ¡ The Lancet.Lancet 2009 HIN1 vaccination editorial - August.pdf

All it takes is just one vaccine to forever change your life. - Dawn, mother of vaccine damaged child.

See the Web's breaking stories, chosen by people like you. Check out Buzz.